Gastroenterology

A recent study’s findings indicate that extending the colonoscopy screening interval could be safe.

A study from University of Gothenburg, Sweden, states that dietary management surpasses medications for irritable bowel syndrome, with about 70% experiencing significant symptom improvement,

GLP1-RA drugs for diabetes may heighten risk of gastric retention during upper endoscopy. Research suggests continued use may not warrant procedure cancellations.

This News Feature explores the current use of anti-TNF combination therapy with immunomodulators for Crohn’s disease and ulcerative colitis in adults and children.

Patients who underwent surgery for inflammatory bowel disease (IBD) reported better physical health 1 month after surgery, according to research. Read more.

Anti-TNF therapy can lead to significant improvement in growth disturbances among children with Crohn’s disease: the number of patients with growth disturbances notably decreased 12 and 24 months after initiation of anti-TNF therapy.

This News Feature explores the current opinions of leading gastroenterologists on the early use of anti-TNFs for Crohn’s disease and ulcerative colitis.

This News Feature explores the changing landscape of inflammatory bowel disease care focusing on personalised approaches and shared decision-making to support therapy selection.